CervoMed Inc. (CRVO) stock
CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$1.50−0.17 (-10.18%)
Close on Nov 17, 2026Market cap $22.68MP/E –Yield –
CervoMed EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
CervoMed's EPS for the twelve months ending Jun 30, 2026 was -$3.21. For fiscal 2022 it was $2038891.00, up 4.7% from the year before. The highest annual figure on record is $53831973.00 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2038891.00 | +4.7% |
| FY2021 | Dec 31, 2021 | $1946859.00 | -96.4% |
| FY2020 | Dec 31, 2020 | $53831973.00 | +702.7% |
| FY2019 | Dec 31, 2019 | $6706509.00 | +106.8% |
| FY2018 | Dec 31, 2018 | $3242301.00 | – |
| FY2017 | Dec 31, 2017 | -$29.11 | – |
| FY2016 | Dec 31, 2016 | -$26.40 | – |
| FY2015 | Dec 31, 2015 | -$38.40 | – |
| FY2014 | Dec 31, 2014 | -$150.00 | – |
| FY2013 | Dec 31, 2013 | -$150.00 | – |
| FY2012 | Dec 31, 2012 | -$1224.00 | – |
| FY2011 | Dec 31, 2011 | -$3900.00 | – |
| FY2010 | Dec 31, 2010 | -$2100.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.64 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.86 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.87 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.84 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.70 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.56 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.77 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.55 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.27 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.41 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.70 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | -$2.75 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | -$1.03 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | -$1.70 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $101903979.00 | +96.1% |
| Q2 FY2021 | Jun 30, 2021 | $101903979.00 | +195.3% |
| Q1 FY2021 | Mar 31, 2021 | $83420184.00 | +1677.4% |
| Q3 FY2020 | Sep 30, 2020 | $64011342.00 | +1524.4% |
| Q2 FY2020 | Jun 30, 2020 | $51978286.00 | +1439.5% |
| Q1 FY2020 | Mar 31, 2020 | $34507496.00 | +923.5% |
| Q3 FY2019 | Sep 30, 2019 | $4693290.00 | +39.3% |
| Q2 FY2019 | Jun 30, 2019 | $3940684.00 | +40.0% |
| Q1 FY2019 | Mar 31, 2019 | $3376230.00 | +112540900.0% |
| Q3 FY2018 | Sep 30, 2018 | $3371468.00 | – |
| Q2 FY2018 | Jun 30, 2018 | $3369770.00 | – |
| Q1 FY2018 | Mar 31, 2018 | $2814316.00 | – |
| Q3 FY2017 | Sep 30, 2017 | $3.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$41.70 | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.73 | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.95 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?